Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT03590769Phase 1Completed
Phase 1, open-label, single-arm trial, sponsored by University of California, San Francisco. Primary endpoint: Changes found in the quantitative measure of FDG-PET uptake at intervention site. Started Jun 2017; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT03590769.